Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. - Wikidata - wikimedia - TriplyDB

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

http://www.wikidata.org/entity/Q44833599

about

Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Quality of outcome reporting in phase II studies in pulmonary tuberculosis A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Pipeline of drugs for related diseases: tuberculosis Challenges in the clinical assessment of novel tuberculosis drugs.Recent advances in tuberculosis: New drugs and treatment regimens.Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.An update on the use of rifapentine for tuberculosis therapy.Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen Evaluation of the Informed Consent Process of a Multicenter Tuberculosis Treatment Trial.TMC207 becomes bedaquiline, a new anti-TB drug.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Nonclinical models for antituberculosis drug development: a landscape analysis.Optimizing the clinical pharmacology of tuberculosis medications.The anti-tuberculosis agents under development and the challenges ahead.Synthetic investigational new drugs for the treatment of tuberculosis.New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.Rifapentine for the treatment of latent tuberculosis.The pharmacological challenges of treating tuberculosis and HIV coinfections.NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Reply to "Contradictory results with high-dosage rifamycin in mice and humans".

P2860

Q26771997-4908DF69-0A56-4213-AFE8-9160880DAC10 Q26777160-CFFCBA5A-6EF8-4FB8-B518-91E43724995A Q27004482-8DC75D72-F9B2-45BE-A361-AD3D7CFA9789 Q28602112-65993BE0-5859-4092-B8FB-55296507ADBE Q28818217-4058A023-6E4C-46EC-AD2E-75596CAB0072 Q30251933-9226EC2E-6457-4AA8-9268-EFF258F5B4B4 Q30360811-A5DCCED6-0D35-4D77-A093-3E55B553A685 Q33585344-06607209-7864-4B0E-BD91-B979CDE4EC47 Q33638930-070C61A1-6C73-4025-81D2-71931EA94278 Q33735589-6988A6A9-1D73-4AB3-8DC4-234D72AAE69A Q33798061-D79B3137-956D-4CBE-9516-5A8EB5B273FF Q34058356-E36079FD-6B10-44E7-9FE9-BBFEE8F830D4 Q34596844-8951FBD9-A7BE-4EF3-962D-C0DB98F273DA Q34700076-3A214EF8-DAB4-4222-A8D2-EB474D321552 Q35084363-65D8443B-3641-4DBE-B032-E3A955D7FBFF Q35105766-F0570F98-6567-49F9-8D69-4016C8065779 Q35607718-36CE3240-69C5-40B9-8B67-28F87EDAD47A Q35687128-48FFB625-661F-41AC-B362-C5F24141199C Q35906959-084BDD7A-BA34-45DC-B792-C1D5A5238E87 Q36012300-FA7A18F6-7CFE-430C-8064-DD15D76C8252 Q36094215-D98FC290-3FA3-4F3C-8B2C-2CA0E3C2F66C Q36115081-FF295443-6886-4044-98A3-DEFB7579AFDA Q36667095-4607F4B4-976A-4263-8C7E-7916F68F22DC Q37036499-25626458-9D03-42AA-9377-F8095B8F6BDF Q37074826-EFA8AF82-53BC-4F44-B511-59030F2AB81E Q37138650-9C511505-77F9-4292-8017-CD610C570349 Q37701965-6E9FA796-79EC-4613-A3CD-281876EB72A8 Q38135901-90743203-1E51-47FC-BD4A-278052F8F4EE Q38213320-80BAF772-7064-4245-B509-6E8C24AD4B50 Q38502294-95AD700B-3BC0-41D9-9ADD-43C0157EABC1 Q38542159-58237012-A6B9-4F32-AEF6-64A3F787FE44 Q38617197-A1FF75B3-6596-4C86-880B-A3AC54406A08 Q38635790-CA6033E9-311E-4F6A-8CDD-460CD50784DD Q38754367-2A4C12E4-7DC4-466D-90E5-AFF43BC6F9D1 Q38851434-480BE4A9-9355-4237-AD1D-A55114C47876 Q38933165-3F1E171C-BA9E-4A61-8300-0DD713EDDFC1 Q39003762-25ABAF03-3E5F-4884-9297-FE734FDED14B Q40087530-51CEB6BD-3651-45E4-B25E-C06882DBE53B Q40095703-1839B608-FA0C-4603-ACEA-911594392ADB Q42952085-D8608241-2ED2-46B1-BC7D-8006B9F729AA

P2860

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

http://www.wikidata.org/entity/Q44833599

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Substitution of rifapentine fo ...... uberculosis trials consortium.

@en

Substitution of rifapentine fo ...... uberculosis trials consortium.

@nl

type

label

Substitution of rifapentine fo ...... uberculosis trials consortium.

@en

Substitution of rifapentine fo ...... uberculosis trials consortium.

@nl

prefLabel

Substitution of rifapentine fo ...... uberculosis trials consortium.

@en

Substitution of rifapentine fo ...... uberculosis trials consortium.

@nl

P1433

Q44833599-C61F876F-4A4D-40DF-A8DC-466B2BF40A68

P1476

Q44833599-4A093C71-7963-4427-A16F-38E19469A8DE

P2093

Q44833599-0E26D907-D79A-4837-A085-71D67598E7F9

Q44833599-2C48AE51-114F-4D65-B46C-874F9ECD33B9

Q44833599-3ED3993F-F6EC-4BBD-983A-CD7B0BF512A5

Q44833599-8089706A-FB39-46A9-AB32-64DEC376846D

Q44833599-87EA82D9-A08A-47AF-8123-509479FEB31B

Q44833599-9219D708-A258-4F21-B97D-AEE535C16CAF

Q44833599-983C0D11-DEE7-47EE-8131-C04107D30E97

Q44833599-98B64619-06E7-4259-8870-A64F4DDACD41

Q44833599-9ACAD8C0-3FE9-4EA1-9FC7-5032610848B1

Q44833599-C159B46E-B2E3-4592-8022-722210065746

P2860

Q44833599-0567B124-9515-43C6-80D5-25B8DABDD49C

Q44833599-066777CB-EED2-49D2-8513-966FE29307C4

Q44833599-18F8B4BC-656B-4D3F-916C-29302A827AA0

Q44833599-3203763A-09C3-4C69-9E18-04C240975E63

Q44833599-3DC6D3E2-58C3-433F-B642-82253F612157

Q44833599-57C8C4DC-1E81-457C-90A8-AF2998744E0A

Q44833599-5EF447F8-2B7F-4545-A201-BB22C4E62949

Q44833599-6411D607-F4C0-44A0-82FD-7E55AA431FED

Q44833599-77716F67-5129-48D9-8680-CDDEED396BDF

Q44833599-890F2DAA-2255-491F-88F9-DC1C0B83655B

P304

Q44833599-B181651E-C528-409D-9E11-8202252379D9

P31

Q44833599-C8871E96-E179-415B-8554-0C05107C72D4

P356

Q44833599-BBDD65A3-5D6F-4B51-BAE3-DC3E3C98D564

P407

Q44833599-0DFF3BAB-43DD-42B9-BF67-59B1D5733040

P433

Q44833599-43FCD3BB-1112-4B80-93D8-5B551C45CF35

P478

Q44833599-1D8B5961-A8E9-4535-9DF5-7520BB520023

P50

Q44833599-79AC2CE0-3BB6-48DD-AC55-D89A232AD754

Q44833599-9DBC65F5-CE35-4E17-A4B9-B09D7FF713A8

P577

Q44833599-F49E5D4D-73D8-45BE-9CC6-2F48668FBB48

P698

Q44833599-6CBC5728-CFA4-443D-87A9-00B16333790D

P921

Q44833599-EDC7822F-F2BC-4955-B6D0-B6ED8278B8E9

P356

P1433

The Journal of Infectious Diseases

P1476

Substitution of rifapentine fo ...... uberculosis trials consortium.

@en

P2093

Andrew Vernon

http://www.w3.org/2001/XMLSchema#string

Betial Haile

http://www.w3.org/2001/XMLSchema#string

Edward Bates

http://www.w3.org/2001/XMLSchema#string

Eric L Nuermberger

http://www.w3.org/2001/XMLSchema#string

Grace Muzanyi

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Lorna Bozeman

http://www.w3.org/2001/XMLSchema#string

Marc Weiner

http://www.w3.org/2001/XMLSchema#string

Masahiro Narita

http://www.w3.org/2001/XMLSchema#string

Neil W Schluger

http://www.w3.org/2001/XMLSchema#string

P2860

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.

Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.

Effect of meals on rifampicin absorption.

Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.

P304

1030-1040

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIS461

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

206

http://www.w3.org/2001/XMLSchema#string

P50

Charles M. Heilig

P577

2012-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22850121

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde